<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Venetoclax: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Venetoclax: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Venetoclax: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="107878" href="/d/html/107878.html" rel="external">see "Venetoclax: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F46443604"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Venclexta;</li>
<li>Venclexta Starting Pack</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872172"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Venclexta;</li>
<li>Venclexta Starting Pack</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F46387202"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent;</li>
<li>
                        Antineoplastic Agent, BCL-2 Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F46439803"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Assess risk for tumor lysis syndrome (TLS) in all patients; administer prophylactic hydration and antihyperuricemics prior to the first venetoclax dose. TLS may also occur upon venetoclax reinitiation following therapy interruption. The ramp-up schedule/dose varies by indication. Also refer to the Azacitidine, Decitabine, Cytarabine, Obinutuzumab, or Rituximab monographs.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad84c70c-a932-492d-bd7b-1b0f109f4056">Acute myeloid leukemia, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia, newly diagnosed:</b> Adults ≥75 years of age or with comorbidities: <b>Note:</b> Initiate azacitidine, decitabine, or low-dose cytarabine on cycle 1, day 1. The venetoclax dose depends upon the concomitant chemotherapy agent. WBC should be &lt;25,000/mm<sup>3</sup> prior to initiation of venetoclax; cytoreduction prior to treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">Day 1: <b>Oral:</b> 100 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Day 2: <b>Oral: </b>200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Day 3: <b>Oral: </b>400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Venetoclax in combination with azacitidine or decitabine:</i> Day 4 and beyond: <b>Oral: </b>400 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30361262','lexi-content-ref-32786187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30361262','lexi-content-ref-32786187'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Venetoclax in combination with low-dose cytarabine: </i>Day 4 and beyond: <b>Oral: </b>600 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30892988','lexi-content-ref-32219442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30892988','lexi-content-ref-32219442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tumor lysis syndrome risk assessment and p</i>
<i>remedication</i>
<i>: </i>Assess patient-specific factors for TLS and provide prophylactic hydration and antihyperuricemic therapy prior to the first venetoclax dose.</p>
<p style="text-indent:-2em;margin-left:6em;">WBC should be &lt;25,000/mm<sup>3</sup> prior to venetoclax initiation; pretreatment cytoreduction may be required.</p>
<p style="text-indent:-2em;margin-left:6em;">Administer adequate hydration and antihyperuricemic agents prior to the first venetoclax dose; continue during the ramp-up phase.</p>
<p style="text-indent:-2em;margin-left:6em;">Assess blood chemistries (potassium, uric acid, phosphorus, calcium, and creatinine) and correct preexisting electrolyte abnormalities prior to venetoclax initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">Monitor blood chemistries for TLS at pre-dose, 6 to 8 hours after each new dose during ramp-up, and 24 hours after reaching final dose.</p>
<p style="text-indent:-2em;margin-left:6em;">For patients at high risk of TLS (eg, circulating blasts, high leukemia burden in the bone marrow, elevated pretreatment lactate dehydrogenase levels, reduced kidney function), consider additional TLS preventative measures, including increased laboratory monitoring and reduced initial venetoclax doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d69dfbae-4438-4fd5-82d1-89796bed4188">Chronic lymphocytic leukemia/small lymphocytic lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia/small lymphocytic lymphoma: Note:</b> The 5-week ramp up schedule is designed to gradually reduce tumor burden and the risk of TLS.</p>
<p style="text-indent:-2em;margin-left:4em;">Week 1: <b>Oral: </b>20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Week 2: <b>Oral: </b>50 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Week 3: <b>Oral: </b>100 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Week 4: <b>Oral: </b>200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Week 5: <b>Oral: </b>400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Venetoclax monotherapy:</i> Week 5 and thereafter: <b>Oral: </b>400 mg once daily; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Venetoclax in combination with obinutuzumab:</i>
<b>Note: </b>Obinutuzumab begins on day 1 of cycle 1; initiate venetoclax on day 22 of cycle 1 according to the 5-week ramp-up schedule for chronic lymphocytic leukemia/small lymphocytic lymphoma above; ramp-up will be completed at the end of cycle 2. Cycle 3 (day 1 and beyond): <b>Oral: </b>400 mg once daily until the end of cycle 12. Each cycle is 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31166681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31166681'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Venetoclax in combination with rituximab:</i> Week 5 and thereafter: <b>Oral: </b>400 mg once daily; continue venetoclax until disease progression or unacceptable toxicity, for up to 24 months from day 1 (cycle 1) of rituximab; begin rituximab after receiving venetoclax at the 400 mg once daily dose for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32986498','lexi-content-ref-29562156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32986498','lexi-content-ref-29562156'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Venetoclax in combination with ibrutinib; fixed treatment duration in previously untreated disease (off-label combination): </i>
<b>Note:</b> Each cycle is 28 days. Begin ibrutinib as a single agent for 3 cycles prior to initiation of venetoclax; venetoclax is ramped up in cycle 4.</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 4 (venetoclax ramp up):</p>
<p style="text-indent:-2em;margin-left:8em;">Week 1: <b>Oral: </b>20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kater.1','lexi-content-ref-34618601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kater.1','lexi-content-ref-34618601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Week 2: <b>Oral: </b>50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kater.1','lexi-content-ref-34618601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kater.1','lexi-content-ref-34618601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Week 3: <b>Oral: </b>100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kater.1','lexi-content-ref-34618601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kater.1','lexi-content-ref-34618601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Week 4: <b>Oral: </b>200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kater.1','lexi-content-ref-34618601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kater.1','lexi-content-ref-34618601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 5 to 15:</p>
<p style="text-indent:-2em;margin-left:8em;">Week 5 and beyond: <b>Oral: </b>400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kater.1','lexi-content-ref-34618601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kater.1','lexi-content-ref-34618601'])">Ref</a></span>). In one study, patients who completed 15 cycles (3 lead in ibrutinib cycles plus 12 ibrutinib/venetoclax combination cycles) were administered 1 additional ibrutinib/venetoclax cycle during which minimal residual disease status and tumor response were assessed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34618601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34618601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tumor lysis syndrome risk assessment and premedication: </i>Assess patient-specific factors for TLS and provide prophylactic hydration and antihyperuricemic therapy prior to the first venetoclax dose (venetoclax causes a rapid reduction in tumor and poses a risk for TLS in the initial 5-week ramp-up phase). The risk of TLS is based on multiple factors, particularly reduced kidney function (CrCl &lt;80 mL/minute) and tumor burden; splenomegaly may also increase the risk of TLS. Perform tumor burden assessments, including radiographic evaluation (eg, CT scan); assess blood chemistries in all patients (potassium, uric acid, phosphorus, calcium, and creatinine; changes in blood chemistries consistent with TLS requiring prompt management can occur as early as 6 to 8 hours following the first venetoclax dose and with each dose increase); correct preexisting abnormalities prior to initiation of venetoclax. Consider all patient comorbidities prior to determining prophylaxis and monitoring schedule. TLS risk may decrease as tumor burden decreases. TLS can also occur upon resumption of venetoclax following a dosage interruption; reassess TLS risk when reinitiating venetoclax following therapy interruption lasting &gt;1 week during the ramp-up phase, or &gt;2 weeks after ramp-up completion. Institute prophylaxis and monitoring as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Low tumor burden (all lymph nodes &lt;5 cm and absolute lymphocyte count [ALC] &lt;25,000/mm<sup>3</sup>): Outpatient: Hydrate with 1.5 to 2 L of oral hydration and administer allopurinol or xanthine oxidase inhibitor (beginning 2 to 3 days prior to venetoclax initiation). Administer IV hydration for patients unable to tolerate oral hydration.</p>
<p style="text-indent:-2em;margin-left:6em;">Medium tumor burden (any lymph node 5 to &lt;10 cm or ALC ≥25,000/mm<sup>3</sup>): Outpatient: Hydrate with 1.5 to 2 L of oral hydration (administer IV hydration for patients unable to tolerate oral hydration; consider additional IV hydration) and administer allopurinol or xanthine oxidase inhibitor (beginning 2 to 3 days prior to venetoclax initiation).</p>
<p style="text-indent:-2em;margin-left:6em;">High tumor burden (any lymph node ≥10 cm OR ALC ≥25,000/mm<sup>3</sup> and any lymph node ≥5 cm): Inpatient: Hydrate with 1.5 to 2 L of oral hydration (administer IV hydration for patients unable to tolerate oral hydration) and 150 to 200 mL/hour IV hydration as tolerated; administer allopurinol or xanthine oxidase inhibitor (beginning 2 to 3 days prior to venetoclax initiation); consider rasburicase if baseline uric acid is elevated. Ramp-up may be completed outpatient if clinically indicated.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e2c38ad-a1a6-4ea9-bf75-256172d10d98">Mantle cell lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mantle cell lymphoma, relapsed or refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Venetoclax monotherapy:</i>
<b>Oral: </b>Initial: 20 mg once daily for week 1, followed by 50 mg once daily for week 2, followed by 100 mg once daily for week 3, followed by 200 mg once daily for week 4, followed by 400 mg once daily for week 5. Week 6 and thereafter: 800 mg once daily until disease progression or unacceptable toxicity occurs or until proceeding to allogeneic stem cell transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28095146','lexi-content-ref-30359156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28095146','lexi-content-ref-30359156'])">Ref</a></span>). Refer to protocols for further details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1c12cde-98c7-41e9-80b8-0893e9934cc7">Multiple myeloma, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed/refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>With translocation t(11;14):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Venetoclax in combination with dexamethasone:</i>
<b>Oral: </b>800 mg once daily; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33368455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33368455'])">Ref</a></span>). Refer to protocol for further information. <b>Note: </b>A venetoclax dose ramp-up phase has been described in some studies; refer to articles for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32012228','lexi-content-ref-29018077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32012228','lexi-content-ref-29018077'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult Drug Interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991739"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Patients with decreased kidney function (CrCl &lt;80 mL/minute estimated using the Cockcroft-Gault formula) may require more intensive prophylaxis and monitoring to reduce the risk of tumor lysis syndrome during treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment likely to be necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35043428','lexi-content-ref-27233802','lexi-content-ref-27558232','lexi-content-ref-35441018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35043428','lexi-content-ref-27233802','lexi-content-ref-27558232','lexi-content-ref-35441018'])">Ref</a></span>). <b>Note:</b> In one retrospective study, the incidence of adverse events was higher in patients with eGFR &lt;45 mL/minute/1.73 m<sup>2</sup>; higher vigilance may be necessary in these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35295611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35295611'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound): Safety and efficacy data are currently limited to case reports. However, no supplemental dose or dosage adjustment likely to be necessary based on pharmacokinetic characteristics of venetoclax (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36098247','lexi-content-ref-31753932','lexi-content-ref-35295611','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36098247','lexi-content-ref-31753932','lexi-content-ref-35295611','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): No safety or efficacy data currently exist. However, no dosage adjustment likely to be necessary based on pharmacokinetic characteristics of venetoclax (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No safety or efficacy data currently exist. However, no dosage adjustment likely to be necessary based on pharmacokinetic characteristics of venetoclax (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No safety or efficacy data currently exist. However, no dosage adjustment likely to be necessary based on pharmacokinetic characteristics of venetoclax (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988573"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment (Child-Pugh classes A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Reduce the daily venetoclax dose by 50%; monitor closely for adverse reactions.</p></div>
<div class="block dot drugH1Div" id="F46439829"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia:</b>
<b>Note: </b>Monitor blood counts frequently until cytopenias resolve. Toxicity may require venetoclax dose interruptions or permanent discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 4 neutropenia (with or without fever or infection) <b>or</b> grade 4 thrombocytopenia:</p>
<p style="text-indent:-2em;margin-left:6em;">Occurring prior to achieving remission: Consider supportive measures, including anti-infectives and WBC growth factors, as clinically necessary. In most instances, do not interrupt treatment cycles (of venetoclax and azacitidine, decitabine, or low-dose cytarabine) due to cytopenias (prior to achieving remission). Bone marrow evaluation is recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">First occurrence after achieving remission and lasting at least 7 days: Delay subsequent treatment cycle (of venetoclax and azacitidine, decitabine, or low-dose cytarabine) and monitor blood counts. Once neutropenia has resolved to ≤ grade 2, resume venetoclax at the same dose in combination with azacitidine, decitabine, or low-dose cytarabine. Consider supportive measures, including anti-infectives and WBC growth factors, as clinically necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Subsequent occurrences in cycles after achieving remission and lasting 7 days or longer: Delay subsequent treatment cycle (of venetoclax and azacitidine, decitabine, or low-dose cytarabine) and monitor blood counts. Once neutropenia has resolved to ≤ grade 2, resume venetoclax at the same dose and reduce the venetoclax duration by 7 days during each subsequent cycle (eg, reduce cycle from 28 days to 21 days). Consider supportive measures, including anti-infectives and WBC growth factors, as clinically necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Nonhematologic toxicities, grade 3 or 4 toxicity (any occurrence): Interrupt venetoclax if not resolved with supportive measures. Resume at the same dose once toxicity is resolved to grade 1 or baseline.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Chronic lymphocytic leukemia/small lymphocytic lymphoma:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Interrupt or reduce dose for toxicities. Reassess risk for tumor lysis syndrome in patients who have had an interruption in dosing of &gt;1 week during ramp-up or &gt;2 weeks after completion of ramp-up (to determine if re-initiation with a reduced dose is necessary).</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Dose Reduction Levels for Venetoclax Toxicity in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</b></caption>
<colgroup><col align="center" class="header-col"/>
<col align="center" class="header-col"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">Dose at interruption</p></th>
<th align="center">
<p style="text-indent:0em;">Restart dose<sup>a</sup></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="2" valign="middle">
<p style="text-indent:0em;">Consider discontinuation for patients who require dose reductions to less than 100 mg for more than 2 weeks.</p></td></tr>
<tr>
<td align="left" colspan="2" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup>During dose escalation phase, continue the reduced dose for 1 week prior to increasing the dose.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">400 mg</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">300 mg</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">200 mg</p></td>
<td align="center">
<p style="text-indent:0em;">100 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">100 mg</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50 mg</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20 mg</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tumor lysis syndrome:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Blood chemistry changes or symptoms suggestive of tumor lysis syndrome (TLS): Withhold the next day's dose.</p>
<p style="text-indent:-2em;margin-left:8em;">If resolved within 24 to 48 hours of the last dose: Resume at the same dose.</p>
<p style="text-indent:-2em;margin-left:8em;">If blood chemistry changes require more than 48 hours to resolve: Resume at a reduced dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Clinical TLS (laboratory TLS with clinical consequences such as acute renal failure, cardiac arrhythmias, and/or seizure): Withhold dose; following resolution, resume at a reduced dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematologic toxicity: Grade 3 neutropenia with infection or fever or grade 4 hematologic toxicities (except lymphopenia):</i></p>
<p style="text-indent:-2em;margin-left:6em;">First occurrence: Interrupt treatment. Resume at the same dose once toxicity is resolved to grade 1 or baseline. Consider supportive measures, including anti-infectives and WBC growth factors, as clinically necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Second and subsequent occurrences: Interrupt treatment. Resume at a lower dose level once toxicity is resolved (see dosage reduction levels in above table; a larger dose reduction may be necessary based on clinical discretion). Consider supportive measures, including anti-infectives and WBC growth factors, as clinically necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonhematologic toxicities, Grade 3 or 4 toxicity:</i></p>
<p style="text-indent:-2em;margin-left:6em;">First occurrence: Interrupt treatment. Resume at the same dose once toxicity is resolved to grade 1 or baseline (no dosage adjustment is necessary).</p>
<p style="text-indent:-2em;margin-left:6em;">Second and subsequent occurrences: Interrupt treatment. Resume at a lower dose level once toxicity is resolved (see dosage reduction levels in above table; a larger dose reduction may be necessary based on clinical discretion).</p></div>
<div class="block doe drugH1Div" id="F46439826"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F46443999"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (67%), hyperkalemia (59%), hypoalbuminemia (49%), hypocalcemia (87%), hyponatremia (40%), hypophosphatemia (45%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (18%), constipation (16%), diarrhea (43%), nausea (42%), stomatitis (13%; grades ≥3: &lt;1%), vomiting (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (33% to 71%; grades ≥3: 18% to 26%), leukopenia (89%; grades 3/4: 42%; grade 4: 11%), lymphocytopenia (11% to 74%; grades ≥3: 7% to 40%; grade 4: 9%), neutropenia (50% to 87%; grades ≥3: 45% to 63%; grade 4: 33%), thrombocytopenia (29% to 64%; grades ≥3: 20% to 31%; grade 4: 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (53%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (14%), fatigue (32%), headache (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (12%), musculoskeletal pain (29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (22%), dyspnea (13%), lower respiratory tract infection (11%), pneumonia (14%), upper respiratory tract infection (36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (6%; grades ≥3: 6%), tumor lysis syndrome (5-week ramp-up phase: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hematologic &amp; oncologic: Hemolytic anemia</p></div>
<div class="block coi drugH1Div" id="F46387205"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant use with strong CYP3A inhibitors at initiation and during ramp-up phase in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) due to the potential for increased risk of tumor lysis syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to venetoclax or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F46439791"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Neutropenia, thrombocytopenia, and anemia may occur. Grade 3 and 4 neutropenia commonly occurred in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients receiving venetoclax, either as monotherapy or in combination with rituximab or obinutuzumab. Neutropenic fever has been reported both with monotherapy and combination therapy. When used in combination with azacitidine, decitabine, or low-dose cytarabine for acute myeloid leukemia (AML), baseline neutrophil counts worsened in almost all patients; neutropenia may occur with subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Serious and fatal infections, including pneumonia and sepsis, have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome (TLS) (including fatalities and kidney failure requiring dialysis) has occurred in patients with high tumor burden when treated with venetoclax. Venetoclax may cause a rapid reduction in tumor volume and therefore a risk for TLS is present during initiation and during the ramp-up phase of treatment (as well as during reinitiation after therapy interruption in CLL/SLL). The use of the ramp-up dose, TLS prophylaxis, and monitoring reduced the rate of TLS in venetoclax monotherapy studies; a shorter ramp up (eg, 2 to 3 weeks) and higher initial doses have resulted in higher rates of TLS and related complications in patients with CLL/SLL. Changes in blood chemistries consistent with TLS may occur as early as 6 to 8 hours after the first venetoclax dose and with each dose increase and require prompt management. The risk for TLS is increased with high tumor burden, comorbidities, and type of malignancy; splenomegaly may also increase TLS risk in CLL/SLL. Reduced kidney function further increases TLS risk. The risk for TLS may decrease as tumor burden decreases. Concomitant use of strong or moderate CYP3A inhibitors or P-gp inhibitors at initiation or during ramp-up may increase the risk for TLS and requires venetoclax dosage modification.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple myeloma: In patients with relapsed or refractory multiple myeloma, an increase in mortality was noted when venetoclax was added to bortezomib and dexamethasone (in patients without the t(11;14) translocation [Kumar 2020]). Relapsed/refractory t(11;14) multiple myeloma is an off-label use for venetoclax.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Live vaccinations should not be administered prior to, during, or after venetoclax treatment until B-cell recovery occurs. Vaccines may be less effective.</p></div>
<div class="block foc drugH1Div" id="F46443605"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Venclexta: 10 mg, 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Venclexta Starting Pack: Week 1: 10 mg (14); Week 2: 50 mg (7); Week 3: 100 mg (7); Week 4: 100 mg (14) (42 ea)</p></div>
<div class="block geq drugH1Div" id="F46443603"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46817117"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Venclexta Starting Pack Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 &amp; 50 &amp; 100 mg (per each): $94.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Venclexta Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $15.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $76.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $152.66</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872173"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Venclexta: 10 mg, 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Venclexta Starting Pack: Week 1: 10 mg (14); Week 2: 50 mg (7); Week 3: 100 mg (7); Week 4: 100 mg (14) (42 ea)</p></div>
<div class="block accres drugH1Div" id="F46439787"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Available through specialty pharmacies and distributors. Further information may be obtained from the manufacturer. </p></div>
<div class="block adm drugH1Div" id="F46439845"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with a meal and water at approximately the same time each day. Swallow whole; do not crush, chew, or break prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed or vomited doses:</i> If a dose is missed and it is within 8 hours of the missed usual dosing time, administer the missed dose as soon as possible and resume the normal daily dosing schedule. If it is more than 8 hours, do not administer the missed dose and resume the usual dosing schedule the next day. If the patient vomits following administration of a dose, no additional doses should be administered that day; administer the next prescribed dose at the usual time.</p></div>
<div class="block hazard drugH1Div" id="F49161144"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Venetoclax may cause teratogenicity and reproductive toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F46502907"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Venclexta: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F208573s026lbl.pdf%23page%3D54&amp;token=eLbz1JVUFw35T4Dtbuo%2FHgce3iP35hjxysbMyjDoFkH%2F%2Ffhj42%2F8%2BbBxVeWnGI01sheBEYu%2FWCWeUWlefwSmYoKbsI2Fn0TjkzNy9SillzsOhFLai6VGYArpyHPi%2B6MI&amp;TOPIC_ID=107696" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208573s026lbl.pdf#page=54</a></p></div>
<div class="block use drugH1Div" id="F46387204"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia:</b> Treatment of newly-diagnosed acute myeloid leukemia (in combination with azacitidine, decitabine, or low-dose cytarabine) in patients ≥75 years of age, or in patients with comorbidities that preclude use of intensive induction chemotherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia/small lymphocytic lymphoma:</b> Treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in adults.</p></div>
<div class="block off-label drugH1Div" id="F53325163"><span class="drugH1">Use: Off-Label: Adult</span><p>Mantle cell lymphoma, relapsed/refractory; Multiple myeloma, relapsed/refractory, t(11;14)</p></div>
<div class="block mst drugH1Div" id="F46439785"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Venetoclax may be confused with vandetanib, vemurafenib, venlafaxine, vismodegib, vorinostat</p>
<p style="text-indent:-2em;margin-left:4em;">Venclexta may be confused with venlafaxine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F46440279"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F46440276"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bitter Orange: May increase the serum concentration of Venetoclax.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Venetoclax.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Venetoclax.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Venetoclax. Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with moderate CYP3A4 inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Venetoclax. Management: Coadministration is contraindicated during venetoclax initiation and ramp-up in CLL/SLL patients. Reduced venetoclax doses are required during ramp-up for patients with AML, and all maintenance therapy. See full Lexi Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Venetoclax may increase the serum concentration of Digoxin.  Management: Avoid concomitant use of venetoclax and digoxin if possible. If combined, administer digoxin at least 6 hours before venetoclax to minimize the potential for an interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: If coadministration with these narrow therapeutic index/sensitive P-gp substrates is unavoidable, separate erdafitinib administration by at least 6 hours before or after administration of these P-gp substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Venetoclax.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Venetoclax. Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with P-glycoprotein (P-gp) inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of Venetoclax. Management: Coadministration is contraindicated during venetoclax initiation and ramp-up in CLL/SLL patients. Reduced venetoclax doses are required during ramp-up for patients with AML, and all maintenance therapy. See full Lexi Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Star Fruit: May increase the serum concentration of Venetoclax.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Venetoclax may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F49002455"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Administration with a low-fat meal (~512 kilocalories; 25% fat calories, 60% carbohydrate calories, and 15% protein calories) increased exposure by ~3.4-fold and administration with a high-fat meal (~753 kilocalories; 55% fat calories, 28% carbohydrate calories, and 17% protein calories) increased exposure by ~5.1- to 5.3-fold, compared to fasting. Management: Administer with a meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Coadministration with grapefruit products, Seville oranges, and/or Star Fruit may increase venetoclax plasma concentrations. Management: Avoid concomitant administration with grapefruit products, Seville oranges, and Star Fruit.</p></div>
<div class="block rep_considerations drugH1Div" id="F53263965"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to initiating venetoclax treatment in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for 30 days after the final venetoclax dose.</p></div>
<div class="block pri drugH1Div" id="F46439789"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, venetoclax is expected to cause fetal harm if administered during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Guidance is available for the management of acute myeloid leukemia during pregnancy (Ali 2015). A case report describes use of venetoclax in a pregnant patient refractory to recommended treatment (Karagiannis 2021).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F46439790"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if venetoclax is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 1 week after the last venetoclax dose.</p></div>
<div class="block dic drugH1Div" id="F46439844"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;">Avoid grapefruit products, Seville oranges, and Star Fruit.</p></div>
<div class="block mop drugH1Div" id="F46439847"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential (throughout treatment); blood chemistries (potassium, uric acid, phosphorus, calcium, and creatinine). Evaluate pregnancy status prior to treatment in patients who could become pregnant. Assess tumor burden, including radiographic evaluation (eg, CT scan), for tumor lysis syndrome (TLS) risk evaluation. Monitor for signs/symptoms of infection. Monitor for adverse reactions in patients with hepatic impairment. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">Blood chemistry monitoring in acute myeloid leukemia: Assess and correct preexisting abnormalities prior to therapy initiation; monitor blood chemistries for TLS prior to first dose, 6 to 8 hours after each new dose during ramp-up, and 24 hours after reaching the final dose. Increased monitoring may be necessary in patients at high risk for TLS.</p>
<p style="text-indent:-2em;margin-left:2em;">Blood chemistry monitoring based on tumor burden/TLS risk in chronic lymphocytic leukemia/small lymphocytic lymphoma:</p>
<p style="text-indent:-2em;margin-left:4em;">Low risk (all lymph node &lt;5 cm and absolute lymphocyte count [ALC] &lt;25,000/mm<sup>3</sup>) or medium risk (any lymph node 5 to &lt;10 cm or ALC ≥25,000/mm<sup>3</sup>): Prior to first dose, 6 to 8 hours, and 24 hours after first 20 mg and 50 mg dose, and prior to each subsequent initial ramp up dose.</p>
<p style="text-indent:-2em;margin-left:4em;">High risk (any lymph node ≥10 cm OR ALC ≥25,000/mm<sup>3</sup> and any lymph node ≥5 cm): Prior to first dose, 4, 8, 12, and 24 hours after first 20 mg and 50 mg dose, and prior to plus 6 to 8 hours and 24 hours after each subsequent initial ramp up dose.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F46439794"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Venetoclax has cytotoxic activity in tumor cells which overexpress BCL-2. Venetoclax selectively inhibits the anti-apoptotic protein BCL-2, which is overexpressed in chronic lymphocytic leukemia (CLL) cells and acute myeloid leukemia (AML) cells. BCL-2 mediates tumor cell survival and has been associated with chemotherapy resistance. Venetoclax binds directly to the BCL-2 protein, displacing pro-apoptotic proteins and restoring the apoptotic process.</p></div>
<div class="block phk drugH1Div" id="F46439796"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 256 to 321 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Highly bound to plasma proteins</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, predominantly via CYP3A; the major metabolite is M27 (has BCL-2 inhibitory activity)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: ~26 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 5 to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (&gt;99.9%; ~21% as unchanged drug); Urine (&lt;0.1%)</p></div>
<div class="block phksp drugH1Div" id="F53517802"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Following a single 50 mg venetoclax dose, systemic exposure (AUC<sub>0 to </sub>
<sub>inf</sub>) was 2.7-fold higher in subjects with severe impairment (Child-Pugh class C), compared to subjects with normal hepatic function.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Based on a study in patients with acute myeloid leukemia enrolled from Asian countries, venetoclax exposure was 63% higher in patients of East-Asian ethnicity (Chinese, Japanese, South Korean, and Taiwanese).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49940153"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Venex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Venetoclax abbvie</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Venclexta | Venclyxto</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ventoxen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Venclexta | Venclexta Starting Pack</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Venclyxto</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Venclixto</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Venclexta</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-HazDrugs.1">
<a name="HazDrugs.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26081614">
<a name="26081614"></a>Ali S, Jones GL, Culligan DJ, et al; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. <i>Br J Haematol</i>. 2015;170(4):487-495. doi:10.1111/bjh.13554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/26081614/pubmed" id="26081614" target="_blank">26081614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32012228">
<a name="32012228"></a>Basali D, Chakraborty R, Rybicki L, et al. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. <i>Br J Haematol</i>. 2020;189(6):1136-1140. doi:10.1111/bjh.16454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/32012228/pubmed" id="32012228" target="_blank">32012228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35043428">
<a name="35043428"></a>Brackman D, Eckert D, Menon R, et al. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. <i>Hematol Oncol</i>. 2022;40(2):269-279. doi:10.1002/hon.2964<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/35043428/pubmed" id="35043428" target="_blank">35043428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29305552">
<a name="29305552"></a>Coutre S, Choi M, Furman RR, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. <i>Blood</i>. 2018;131(15):1704-1711.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/29305552/pubmed" id="29305552" target="_blank">29305552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28095146">
<a name="28095146"></a>Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. <i>J Clin Oncol</i>. 2017;35(8):826-833. doi: 10.1200/JCO.2016.70.4320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/28095146/pubmed" id="28095146" target="_blank">28095146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30359156">
<a name="30359156"></a>Davids MS, von Keudell G, Portell CA, et al. Revised dose ramp-up to mitigate the risk of tumor lysis syndrome when initiating venetoclax in patients with mantle cell lymphoma. <i>J Clin Oncol</i>. 2018;36(35):3525-3527. doi: 10.1200/JCO.18.00359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/30359156/pubmed" id="30359156" target="_blank">30359156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32786187">
<a name="32786187"></a>DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. <i>N Engl J Med</i>. 2020;383(7):617-629. doi:10.1056/NEJMoa2012971<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/32786187/pubmed" id="32786187" target="_blank">32786187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30361262">
<a name="30361262"></a>DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. <i>Blood</i>. 2019;133(1):7-17. doi: 10.1182/blood-2018-08-868752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/30361262/pubmed" id="30361262" target="_blank">30361262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36098247">
<a name="36098247"></a>Edahiro T, Ureshino H, Chishaki R, et al. Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis. <i>Leuk Lymphoma</i>. 2022;63(14):3511-3512. doi:10.1080/10428194.2022.2123230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/36098247/pubmed" id="36098247" target="_blank">36098247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30190341">
<a name="30190341"></a>Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. <i>Haematologica</i>. 2019;104(2):e68-e71. doi: 10.3324/haematol.2018.198812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/30190341/pubmed" id="30190341" target="_blank">30190341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31166681">
<a name="31166681"></a>Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. <i>N Engl J Med</i>. 2019;380(23):2225-2236. doi: 10.1056/NEJMoa1815281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/31166681/pubmed" id="31166681" target="_blank">31166681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27233802">
<a name="27233802"></a>Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin's lymphoma patients: a pooled population pharmacokinetic analysis. <i>AAPS J</i>. 2016;18(5):1192-1202. doi:10.1208/s12248-016-9927-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/27233802/pubmed" id="27233802" target="_blank">27233802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33222152">
<a name="33222152"></a>Karagiannis P, Alsdorf W, Tallarek AC, et al. Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone. <i>Br J Haematol.</i> 2021;192(2):e60-e63. doi:10.1111/bjh.17220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/33222152/pubmed" id="33222152" target="_blank">33222152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kater.1">
<a name="Kater.1"></a>Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. <i>NEJM Evidence</i>. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200006. Published May 13, 2022. Accessed May 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32986498">
<a name="32986498"></a>Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. <i>J Clin Oncol</i>. 2020;38(34):4042-4054. doi:10.1200/JCO.20.00948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/32986498/pubmed" id="32986498" target="_blank">32986498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33368455">
<a name="33368455"></a>Kaufman JL, Gasparetto C, Schjesvold FH, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. <i>Am J Hematol.</i> 2021;96(4):418-427. doi:10.1002/ajh.26083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/33368455/pubmed" id="33368455" target="_blank">33368455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33129376">
<a name="33129376"></a>Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncol</i>. 2020;21(12):1630-1642. doi:10.1016/S1470-2045(20)30525-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/33129376/pubmed" id="33129376" target="_blank">33129376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29018077">
<a name="29018077"></a>Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. <i>Blood</i>. 2017;130(22):2401-2409. doi:10.1182/blood-2017-06-788786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/29018077/pubmed" id="29018077" target="_blank">29018077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2013;24(suppl 6):vi160-70. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26639348">
<a name="26639348"></a>Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>N Engl J Med</i>. 2016;374(4):311-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/26639348/pubmed" id="26639348" target="_blank">26639348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27558232">
<a name="27558232"></a>Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. <i>J Clin Pharmacol</i>. 2017;57(4):484-492. doi:10.1002/jcph.821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/27558232/pubmed" id="27558232" target="_blank">27558232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29562156">
<a name="29562156"></a>Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. <i>N Engl J Med.</i> 2018;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/29562156/pubmed" id="29562156" target="_blank">29562156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27178240">
<a name="27178240"></a>Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncol</i>. 2016;17(6):768-778.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/27178240/pubmed" id="27178240" target="_blank">27178240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35441018">
<a name="35441018"></a>Sugiura H, Sezaki N, Ishikawa T, et al. Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease. <i>Clin Case Rep</i>. 2022;10(4):e05735. doi:10.1002/ccr3.5735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/35441018/pubmed" id="35441018" target="_blank">35441018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31753932">
<a name="31753932"></a>Swan D, Delaney C, Natoni A, O'Dwyer M, Krawczyk J. Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14). <i>Haematologica</i>. 2020;105(3):e141-e143. doi:10.3324/haematol.2019.228338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/31753932/pubmed" id="31753932" target="_blank">31753932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35295611">
<a name="35295611"></a>Szita VR, Mikala G, Kozma Aet al. Targeted venetoclax therapy in t(11;14) multiple myeloma: real world data from seven Hungarian centers. <i>Pathol Oncol Res</i>. 2022;28:1610276. doi:10.3389/pore.2022.1610276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/35295611/pubmed" id="35295611" target="_blank">35295611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 3, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Venclexta.1">
<a name="Venclexta.1"></a>Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Venclexta.2">
<a name="Venclexta.2"></a>Venclexta (venetoclax) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32219442">
<a name="32219442"></a>Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. <i>Blood</i>. 2020;135(24):2137-2145. doi:10.1182/blood.2020004856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/32219442/pubmed" id="32219442" target="_blank">32219442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30892988">
<a name="30892988"></a>Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. <i>J Clin Oncol</i>. 2019;37(15):1277-1284. doi: 10.1200/JCO.18.01600.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/30892988/pubmed" id="30892988" target="_blank">30892988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34618601">
<a name="34618601"></a>Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. <i>J Clin Oncol</i>. 2021;39(34):3853-3865. doi:10.1200/JCO.21.00807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/34618601/pubmed" id="34618601" target="_blank">34618601</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 107696 Version 209.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
